Cite
HARVARD Citation
Lawitz, E. et al. (n.d.). IDDF2018-ABS-0111 Safety and efficacy of treatment with once-daily LEDIPASVIR/SOFOSBUVIR (90/400 MG) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment. Gut. pp. A99-A100. [Online].